JMJD6 and renal cell carcinoma: In line with expectations, we found that overexpressed JMJD6 significantly attenuated sunitinib efficacy compared with that observed in the control group, whereas JMJD6 depletion sensitized RCC cells to sunitinib (Figure S4D).